Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SWTX - SpringWorks Therapeutics Inc


IEX Last Trade
41.7
0.770   1.847%

Share volume: 570,658
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$40.93
0.77
1.88%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
21%
Profitability 25%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
1.36%
1 Month
13.56%
3 Months
-2.11%
6 Months
-14.19%
1 Year
44.43%
2 Year
55.46%
Key data
Stock price
$41.70
P/E Ratio 
0.00
DAY RANGE
$40.98 - N/A
EPS 
$0.00
52 WEEK RANGE
$18.00 - $53.92
52 WEEK CHANGE
$0.38
MARKET CAP 
3.098 B
YIELD 
N/A
SHARES OUTSTANDING 
74.273 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$880,621
AVERAGE 30 VOLUME 
$971,671
Company detail
CEO: Saqib Islam
Region: US
Website: springworkstx.com
Employees: 261
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.

Recent news